Related Experiment Video

Updated: Jun 1, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Association between gene alteration and drug-sensitivity in human lung-carcinoma cell-lines

Y Mizushima, T Kashii, M Kobayashi

    Oncology Reports
    |May 21, 2011
    PubMed

    Insights

    Gene alterations in K-ras and p53 showed no link to lung cancer drug resistance. However, N-myc amplification may increase resistance to common chemotherapy drugs like CDDP and CBDCA.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Lung carcinoma is a leading cause of cancer death.
    • Drug resistance significantly limits the efficacy of chemotherapy for lung cancer.
    • Identifying genetic markers associated with drug resistance is crucial for personalized treatment.

    Purpose of the Study:

    • To investigate the association between specific gene alterations (K-ras, p53, N-myc) and in vitro resistance to four common chemotherapy drugs (CDDP, CBDCA, MMC, Epi-ADM) in human lung carcinoma cell lines.

    Main Methods:

    • Utilized the MTT assay to determine drug sensitivity (IC50 values).
    • Analyzed 29 human lung carcinoma cell lines.
    • Compared IC50 values between cell lines with and without specific gene alterations (K-ras, p53, N-myc).

    Main Results:

    • No significant difference in drug IC50 values was observed for K-ras or p53 gene alterations.
    • Cell lines with N-myc amplification exhibited significantly higher resistance to all four tested drugs compared to those without amplification.
    • These findings suggest a potential role for N-myc in mediating chemoresistance.

    Conclusions:

    • K-ras and p53 gene alterations are unlikely to be major determinants of resistance to CDDP, CBDCA, MMC, and Epi-ADM in lung carcinoma.
    • N-myc gene amplification may be a predictive biomarker for resistance to these chemotherapy agents in lung cancer.
    • Further research is warranted to confirm the role of N-myc in drug resistance and explore therapeutic strategies targeting this pathway.

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

    Published on: April 6, 2016

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Cancer02:18

    Cancer

    Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...